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Abstract Human CD83 (hCD83) is a glycoprotein expressed
predominantly on the surface of dendritic cells (DC) and
represents the best marker for mature DC. Here, we report the
cloning of the cDNA encoding mouse CD83 (mCD83) from a
murine bone marrow-derived DC (BM-DC) cDNA library. DNA
sequence analysis revealed a 196 amino acid protein including a
signal peptide of 21 amino acids which shares 63% amino acid
identity with hCD83. Using Northern blot analyses, mCD83
mRNA was found to be strongly expressed in mouse BM-DC and
its expression was upregulated following stimulation with LPS or
TNF-K. Transfection experiments using COS-7 cells revealed
that mCD83 is glycosylated. Furthermore, the extracellular
CD83 domain was recombinantly expressed in Escherichia coli
and one-dimensional NMR data strongly support that the protein
is structurally folded.
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1. Introduction
Human CD83 (hCD83) is a 45 kDa glycoprotein which
belongs to the immunoglobulin superfamily. It is expressed
predominantly on the surface of dendritic lineage cells, includ-
ing skin Langerhans cells, circulating dendritic cells (DC) and
interdigitating reticulum cells present in the T-cell areas of
lymphoid organs [1^3]. hCD83 is also expressed on mono-
cyte-derived DC after stimulation with in£ammatory cyto-
kines [4]. It consists of an extracellular Ig-like domain, a
transmembrane domain and a 39 amino acid intracellular do-
main [2,5]. Although the function of hCD83 is still unknown,
its selective expression and the upregulation of the expression
of CD83 together with the co-stimulatory molecules CD80
and CD86 during DC maturation suggest an important role
of CD83 in the immune response.
Furthermore, in the human system, we could show that
inhibition of CD83 expression, by interfering with a speci¢c
RNA export pathway, leads to a dramatic reduction of the
DC-mediated T-cell stimulation [6].
DC are the most potent antigen presenting cells of the im-
mune system. In their immature stage, they reside in periph-
eral tissues. Upon encounter with antigen, like pathogens or
tumor antigens, they migrate to lymphoid organs where
they trigger a speci¢c T-cell response [7]. In vitro, immature
DC can be generated from peripheral blood monocytes by
culturing them in the presence of granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin (IL-)
4 [8,9]. These cells show a high endocytic but low T-cell
stimulatory capacity. Upon addition of monocyte-conditioned
medium (MCM) [10] or a cytokine cocktail (IL-1L, IL-6,
tumor necrosis factor K (TNF-K) and PGE2) that mimicks
MCM, these DC develop into fully mature immunostimula-
tory cells [11], which express high levels of CD83, CD80 and
CD86.
Here, we report the molecular cloning of the cDNA encod-
ing mouse CD83 (mCD83). We show that mCD83 mRNA is
highly expressed in bone marrow-derived DC (BM-DC) and
that in mature DC, its expression is upregulated after stimu-
lation with lipopolysaccharide (LPS) or TNF-K. In addition,
we demonstrate that mCD83 is glycosylated when expressed
in COS-7 cells. Furthermore, one-dimensional (1-D) nuclear
magnetic resonance (NMR) data strongly support that the
recombinantly expressed extracellular CD83 domain is struc-
turally folded.
2. Materials and methods
2.1. Generation of a mCD83 speci¢c polymerase chain reaction (PCR)
probe
In order to generate a mCD83 speci¢c screening probe, PCR
primers were deduced from an EST sequence (accession number
AA120620), encoding a partial mCD83 sequence. The following prim-
ers were used to amplify a 152 bp fragment: mCD83 sense 5P-CTT
GAC ACT CAT CAT TTT CAC CTG CAA-3P, mCD83 antisense 5P-
ATC CTA CTC ATA CCG TTT CTG TCT TAG-3P. PCR reactions
included 0.5 WM of each primer, 200 WM dNTP, 1 U Taq polymerase
(Amersham Pharmacia Biotech, Freiburg, Germany) in the supplied
reaction bu¡er. The PCR cycling conditions were as follows: 45 s at
94‡C, 45 s at 64‡C, 90 s at 72‡C. The PCR ampli¢cation was carried
out for 35 cycles and included an initial 5 min denaturation step at
94‡C and a ¢nal 10 min extension at 72‡C. Using these conditions, a
mCD83 speci¢c fragment of 152 bp was ampli¢ed from a mouse BM-
DC cDNA library.
2.2. Isolation of a mCD83 cDNA
The 32P-labelled 152 bp PCR fragment was used to screen a mouse
BM-DC cDNA library [12]. Plaques which were positive after hybrid-
ization were puri¢ed and in vivo excision was performed. Resulting
plasmids were sequenced in both orientations (Sequiserv, Vaterstetten,
Germany).
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 4 6 5 - 9
*Corresponding author. Fax: (49) (9131) 8536417.
E-mail: susanne.berchtold@derma.med.uni-erlangen.de
Abbreviations: DC, dendritic cells; GM-CSF, granulocyte-macro-
phage colony-stimulating factor; LPS, lipopolysaccharide; PCR,
polymerase chain reaction; TNF-K, tumor necrosis factor K ; NMR,
nuclear magnetic resonance
FEBS 22899 11-11-99
FEBS 22899 FEBS Letters 461 (1999) 211^216
2.3. Generation of mouse DC from bone marrow
BM-DC were generated as described [13]. Brie£y, bone marrow
cells were plated onto bacteriological petri dishes (Falcon, Becton
Dickinson, Heidelberg, Germany) at a density of 2U105/ml in
RPMI 1640 medium supplemented with 2 mM L-glutamine (Life
Technologies, Karlsruhe, Germany), 100 IU/ml penicillin (Sigma, De-
isenhofen, Germany), 100 Wg/ml streptomycin (Sigma), 50 WM 2-mer-
captoethanol (Sigma) and 10% heat-inactivated fetal calf serum (FCS)
(PAA, Co«lbe, Germany) (also termed complete medium). GM-CSF
was added as culture supernatant from a cell line transfected with the
murine GM-CSF gene [14] in a ¢nal concentration of 10% which was
found to generate BM-DC equally well to 200 U/ml rmGM-CSF. On
day 3, cells were fed with 10 ml of fresh medium containing 10% GM-
CSF. On day 6, 10 ml of the culture supernatant was collected, cen-
trifuged and the cell pellet resuspended in 10 ml complete medium
containing 10% GM-CSF was reseeded into a new dish. On day 7 or
8, non-adherent cells were rinsed o¡ the plates, centrifuged, resus-
pended in 10 ml complete medium supplemented with 10% GM-
CSF and transferred to new dishes. Cells were stimulated with LPS
(1 Wg/ml, Sigma), TNF-K (500 U/ml, Peprotech/Tebu, Frankfurt, Ger-
many) or K-CD40 (5 Wg/ml) (Pharmingen, Hamburg, Germany) for
24^48 h.
2.4. FACS analysis
The maturation and di¡erentiation status of DC was determined by
staining for the surface markers CD86 (B7-2, FITC-conjugated, Phar-
mingen) and MHCII molecules I-A/I-E (2G9, PE-conjugated, Phar-
mingen). Staining and washing was performed in phosphate-bu¡ered
saline (PBS) (136 mM NaCl, 8 mM Na2HPO4, 1.5 mM KH2PO4,
2.7 mM KCl, pH 7.4) supplemented with 1% FCS. Cells were incu-
bated for 30 min on ice with each antibody in the appropriate dilu-
tion. After washing once with PBS, samples were analyzed with a
FACScan (Becton Dickinson, Heidelberg, Germany).
2.5. Northern blot analysis
Total cellular RNA was isolated using TriFast reagent (Peqlab,
Erlangen, Germany) according to the manufacturer’s instructions.
For Northern blots, 15 Wg of total RNA was separated on formalde-
hyde denaturing gels and blotted onto nitrocellulose. Hybridization
was performed at 42‡C in a solution of 50% (v/v) formamide, 5USSC
(0.75 M NaCl, 0.075 M Na3O7C6H5), 20 mM Na2HPO4/NaH2PO4
pH 6.5, 0.025% Denhardt, 10 Wg/ml herring sperm DNA, using a 1319
bp mCD83 cDNA fragment as probe. Labelling with [K-32P]dATP
was performed using the Random Prime DNA labelling kit (Boehr-
inger Mannheim, Mannheim, Germany). The ¢lter was washed three
times for 20 min at 50‡C with 1USSC and exposed to X-ray ¢lm for
autoradiography. In order to control for the amount of RNA bound,
¢lters were stripped after the exposure and re-hybridized with a
L-actin cDNA probe.
2.6. Antibodies and immunoblotting analysis
The RGS-6UHIS-tag speci¢c antibody was obtained from Qiagen
(Hilden, Germany). For immunoblotting, cells were lysed in lysis
bu¡er (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl pH 7.5,
5 mM EGTA, 5 mM Na3VO4; 10 Wg/ml leupeptin, 2 Wg/ml aprotinin,
1 mM Pefabloc (Boehringer Mannheim)) for 10 min on ice and the
insoluble material was removed by centrifugation. Cleared lysates
were separated on 15% sodium dodecyl sulfate (SDS)-polyacrylamide
gels and blotted onto nitrocellulose ¢lters. The membranes were
blocked with 2% BSA in TBST (20 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.05% Tween 20) for 1 h or overnight. Incubation with speci¢c
antibodies was performed overnight at 4‡C or for 1 h at room temper-
ature. After washing ¢ve times with TBST, ¢lters were incubated with
an appropriate secondary antibody coupled to horseradish peroxidase.
Immunoreactive bands were visualized using an epichemiluminescence
Western blotting system (Amersham Pharmacia Biotech) according to
the manufacturer’s protocol.
2.7. Expression of in vitro transcribed/translated mCD83
Sequences encoding di¡erent domains of mCD83 were cloned in
both orientations into the EcoRI site of the pcDNA3.1 vector (Invi-
trogen, San Diego, CA, USA) to generate the plasmids pmCD83s
(sense) (amino acids 1^196), pmCD83as (antisense), pmCD83-SPs
(amino acids 20^196), pmCD83-SPas, pmCD83 ext. s (amino acids
20^135), pmCD83 ext. as, for in vitro transcription with T7 polymer-
ase. One Wg of all plasmids was in vitro transcribed and translated
using the TNT system (Promega, Madison, WI, USA) with
[35S]cysteine (Amersham Pharmacia Biotech). The radioactively la-
belled mCD83 proteins were separated on 15% polyacrylamide gels
and visualized by autoradiography.
2.8. Expression of mCD83 in COS-7 cells
COS-7 cells were maintained in DMEM medium supplemented
with 10% heat-inactivated FCS, 2 mM glutamine, 100 IU/ml penicillin
and 100 Wg/ml streptomycin. Transfection experiments were per-
formed using the calcium phosphate precipitation technique. Semi-
con£uent COS-7 cells were transfected with 15 Wg of the expression
plasmid encoding mCD83 provided with a C-terminal HIS-tag. After
48 h, the cells were lysed.
2.9. Deglycosylation assay
Lysates of transfected COS-7 cells were incubated with PNGase F
(New England Biolabs, Schwalbach, Germany) for 1 h at 37‡C in the
supplied bu¡er according to the manufacturer’s instructions. Proteins
were separated by SDS-polyacrylamide gel electrophoresis (PAGE)
and blotted onto nitrocellulose. The immunoreaction was performed
with an antibody against the RGS-6UHIS epitope.
2.10. Recombinant expression of the extracellular CD83 domain in
Escherichia coli
Using the full length mCD83 cDNA clone as a template, the ex-
tracellular domain (amino acids 20^135) was PCR-ampli¢ed using
mCD83 pQE sense 5P-GGG GAT CCA TGG CGA TGC GGG
AGG TGA CG-3P and mCD83 pQE antisense 5P-GGG GTA CCT
CAT TCT GCC CTG TAC TTC CTG AAA GT-3P as primers. The
ampli¢ed cDNA fragment was veri¢ed by sequencing and cloned
into the BamHI and KpnI sites of the expression vector pQE30
(Qiagen, Hilden, Germany) resulting in the plasmid pQE30mCD83
ext. The fusion protein contained six histidine residues at the ami-
no-terminus.
2.11. Puri¢cation of the recombinant protein mCD83 ext.
An overnight bacterial culture was diluted 1:60 in fresh LB medium
(supplemented with 100 Wg/ml ampicillin, 25 Wg/ml kanamycin). At an
optical density of 0.6, IPTG was added (¢nal concentration 1 mM)
and the culture proceeded for a further 4 h. The cells were pelletted
and resuspended in 5 ml bu¡er B (8 M urea, 0.1 M NaH2PO4, 0.01 M
Tris-HCl) pH 8.0 per g pellet. After 45 min at room temperature while
stirring, the lysate was spun at 8000Ug. The supernatant was added
to Ni2-NTA-agarose (Qiagen) (1.5 ml per g pellet) equilibrated in
bu¡er B and mixed for 45 min at room temperature. The resin was
packed into a column and washed with 10 volumes bu¡er B (pH 8.0)
and 10 volumes bu¡er B (pH 6.3). The protein was eluted with bu¡er
B (pH 4.5) in 1.5 ml fractions. Protein containing fractions were
dialyzed against 10 mM Tris-HCl (pH 8.0) and loaded onto an anion
exchange column (Mono Q, Amersham Pharmacia Biotech). Proteins
were separated by a linear salt gradient (bu¡er A: 10 mM Tris-HCl,
pH 8.0; bu¡er B: 10 mM Tris-HCl, pH 8.0, 0.5 M NaCl). The correct
amino acid sequence of the puri¢ed protein was veri¢ed by N-terminal
amino acid sequencing (Toplab, Mu«nchen, Germany).
2.12. 1-D NMR studies
1-D NMR spectra were recorded with a sample of the extracellular
CD83 domain using a Bruker AM 400 spectrometer at a temperature
of 300 K. Chemical shift values were determined using acetone as an
internal reference at 2.214 parts per million (ppm). Prior to Fourier
transformation, the free induction decays were zero-¢lled from 8192
to 16 384 data points and a line broadening factor of 32 Hz was
applied.
3. Results and discussion
3.1. Isolation and characterization of a mCD83 cDNA clone
PCR was used to generate a 152 bp mCD83 speci¢c ‘screen-
ing’ fragment using a mouse BM-DC cDNA as template. This
152 bp fragment was then used to screen a mouse BM-DC
cDNA library. One full length clone denominated pSB-1, en-
coding 2051 bp, was isolated and sequenced. It contained an
open reading frame of 588 bp encoding a protein of 196 ami-
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no acids. The complete nucleotide and amino acid sequences
are depicted in Fig. 1. The N-terminal 21 amino acids corre-
sponded to a signal peptide resulting in a mature protein of
175 amino acids. The protein was composed of an extracel-
lular domain consisting of a single Ig-like domain, a trans-
membrane region and a short cytoplasmic domain of 39 ami-
no acids. The cDNA insert contained 13 bp of the 5P-
untranslated region and 1447 bp of the 3P-untranslated region.
mCD83 and hCD83 share an amino acid identity of 63%.
3.2. In vitro transcription/translation of mCD83
Di¡erent domains of mCD83 encoding full length mCD83,
mCD83 lacking the signal peptide or only the extracellular
part of mCD83 were cloned in both orientations into the
expression vector pcDNA3.1. Coupled in vitro transcription/
translation in the presence of [35S]cysteine resulted in the syn-
thesis of radiolabelled proteins of the expected molecular
masses (Fig. 2, lanes 1, 3 and 5). In contrast, no signal was
detectable when the corresponding control antisense sequen-
Fig. 1. Nucleotide and predicted amino acid sequence of the mCD83 cDNA clone pSB-1. The deduced amino acid sequence is shown below
the nucleotide sequence. Numbers along the right margin designate the nucleotide positions with the translation initiation codon demarking nu-
cleotide 1.
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ces were transcribed in this in vitro reaction (Fig. 2, lanes 2, 4
and 6).
3.3. mCD83 is highly expressed in BM-DC and upregulated
after stimulation
Since hCD83 was shown to be expressed predominantly on
the surface of dendritic lineage cells, we analyzed the expres-
sion of mCD83 in mouse BM-DC. Cells were cultured in the
presence of GM-CSF to obtain immature DC, under standard
conditions or additionally stimulated for 24 h with LPS or
TNF-K, to obtain mature DC re£ected by increased expres-
sion of MHCII and CD86, as analyzed by FACS analyses.
Northern blot analyses showed prominent expression of an
approximately 2.4 kb speci¢c mCD83 RNA in BM-DC
(Fig. 3, lanes 1 and 2). Importantly, after stimulation with
LPS (Fig. 3, lane 3) or TNF-K (data not shown), the expres-
sion of mCD83 was strongly upregulated. A20, a B-cell line,
expressed low levels of mCD83, in the T-cell lines DO11 and
3DO, no mCD83 mRNA was detectable (Fig. 3, lanes 4^6).
J774, a monocyte/macrophage-like cell line, showed weak ex-
pression of mCD83 mRNA, whereas in EL4, a di¡erent T-cell
line, no expression could be detected by reverse transcription-
PCR (data not shown).
3.4. mCD83 is glycosylated in COS-7 cells
Since mCD83 contains three potential N-linked glycosyla-
tion attachment sites in its extracellular domain, we investi-
gated whether or not the protein is glycosylated. Therefore,
COS-7 cells were transfected with vectors expressing either the
full length mCD83 or the extracellular domain of mCD83
(mCD83 ext.) as C-terminal HIS-tag fusion proteins. After
48 h, lysates were prepared and digested with PNGase F
(Fig. 4, lanes 4 and 6) or left untreated (Fig. 4, lanes 3 and
5). Lysates of COS-7 cells transfected with the vector alone
served as controls (pcDNA3.1) (Fig. 4, lanes 1 and 2). Pro-
teins were analyzed in Western blots using an antibody di-
rected against the HIS-tag. Undigested proteins migrated at
a position corresponding to a molecular weight of approxi-
mately 30 kDa (mCD83, Fig. 4, lane 3) and 20 kDa (mCD83
ext., Fig. 4, lane 5), respectively.
In sharp contrast, after digestion with PNGase F, both the
full length protein as well as the extracellular CD83 domain
migrated at a lower molecular mass (Fig. 4, lane 4 and 6,
respectively). This corresponds to the molecular weight of E.
coli-expressed CD83 proteins, which are not glycosylated
(data not shown). These data clearly show that in COS-7 cells,
the extracellular domain of CD83 is glycosylated.
Fig. 2. Autoradiography of reticulocyte extracts expressing sense
(lanes 1, 3 and 5) or antisense (lanes 2, 4 and 6) mCD83 constructs.
The constructs included either the signal peptide (mCD83) or lacked
it (mCD83-SP) or comprised only the extracellular domain (mCD83
ext.). Proteins were separated on 15% SDS-PAGE.
Fig. 3. Northern Blot analysis of total RNA. Fifteen Wg of total
RNA was loaded as indicated on top of each lane. Hybridization
was performed with a 1319 bp mCD83 cDNA fragment (upper pan-
el). The blot was reprobed with a L-actin cDNA probe to control
for equal RNA loading (lower panel).
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3.5. Recombinant expression of the extracellular mCD83
domain and 1-D NMR analyses
For NMR studies, the extracellular domain of mCD83
(mCD83 ext.) was expressed in E. coli as a 6UHIS fusion
protein. Since the protein was mainly produced in inclusion
bodies, the puri¢cation by Ni2-NTA-agarose had to be per-
formed under denaturing conditions. After an additional pu-
ri¢cation step using an anion exchange column, the protein
was more than 95% pure.
The 1-D NMR spectrum of the extracellular CD83 domain
at 300 K shows chemical dispersion, i.e. non-random coil
peaks, typical of a structured protein (Fig. 5). In particular,
the presence of slowly exchanging amide resonances (V7^9
ppm) indicates that certain parts of the protein back-bone are
protected from solvent. Down¢eld-shifted K-CH resonances
(V4.5^5.7 ppm) are indicative of L-structures. Up¢eld-shifted
methyl resonances (c6 0.9 ppm) provide further evidence of
the protein being folded. In conclusion, these NMR data
strongly support that the recombinantly expressed extracellu-
lar domain of CD83 is structurally folded. Therefore, this
protein will be used for further functional and structural stud-
ies in order to elucidate the mode of action of CD83 during
DC maturation and to determine the three-dimensional struc-
ture of CD83.
Here, we report the molecular cloning and characterization
of mCD83, a 175 amino acid glycoprotein which is strongly
expressed in BM-DC. mCD83 shares 63% amino acid identity
with hCD83 with the highest homology present within the
transmembrane and cytoplasmic domain. Similar to human
monocyte-derived DC, where the expression of hCD83 is up-
regulated after cytokine stimulation, we found a strong in-
crease in mCD83 mRNA expression after stimulation with
TNF-K or LPS, indicating a function of mCD83 in mature
DC. Deglycosylation experiments revealed that mCD83
undergoes prominent post-translational modi¢cations. Future
gene targeting experiments will help to elucidate the function
of mCD83.
During the completion of this work, another group also
reported the cDNA cloning of mCD83 showing the same
amino acid sequence [15]. In contrast to the here reported
cDNA sequence, which was derived from a full length
cDNA clone, the sequence reported by Twist et al. was de-
duced from a PCR ampli¢cation product. Furthermore, the
authors did not report any additional characterization regard-
ing the induction of mCD83 in mature DC, nor on post-trans-
lational modi¢cations or on recombinant and structural as-
pects.
Therefore, our data allow for further characterization of
mCD83 and the cDNA cloning as well as the recombinant
expression of CD83 provide important tools for the functional
understanding of CD83 and DC biology.
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